Polyethylenimine Linear (PEI), MW 40,000: High-Efficiency DNA Transfection Reagent for In Vitro Studies

Executive Summary: Polyethylenimine Linear (PEI), MW 40,000 is a cationic polymer optimized for DNA transfection in vitro, offering 60–80% efficiency in HEK-293 and comparable mammalian cell lines under serum-containing conditions [APExBIO product page]. Its mechanism involves DNA condensation into positively charged complexes, driving uptake by endocytosis (Roach 2024). The reagent is scalable from 96-well plates to 100-liter bioreactors, supporting transient gene expression and recombinant protein production. Proper storage at -20°C ensures long-term stability, while 4°C is suitable for routine use. PEI, MW 40,000 is validated for broad cell line compatibility and workflow flexibility (internal analysis).

Biological Rationale

Efficient and reproducible gene delivery is essential for in vitro molecular biology and bioproduction workflows. Mammalian cell lines, including HEK-293, CHO-K1, HepG2, and HeLa, are frequently used for recombinant protein production, functional genomics, and transient gene expression studies [APExBIO]. Negatively charged nucleic acids such as DNA require a compatible carrier to traverse the anionic cell membrane. Polyethylenimine Linear (PEI), MW 40,000, a synthetic cationic polymer, effectively condenses DNA to form nanoscale complexes that interact with cell surface proteoglycans and facilitate cellular uptake (Roach 2024). Its serum compatibility and scalability make it a preferred option for both research and industrial applications (see internal benchmark).

Mechanism of Action of Polyethylenimine Linear (PEI), MW 40,000

Polyethylenimine Linear (PEI), MW 40,000 is a polymer with a high density of primary and secondary amines, providing a strong positive charge under physiological pH (Roach 2024). When mixed with DNA, PEI neutralizes and condenses the polyanionic phosphate backbone, forming nanoscale, positively charged complexes. These complexes interact electrostatically with negatively charged glycosaminoglycans (e.g., heparan sulfate proteoglycans) on the cell surface. The resulting particle–cell interactions facilitate endocytosis-mediated uptake. Once internalized, PEI’s buffering capacity—the ‘proton sponge’ effect—promotes endosomal escape, enhancing the probability of DNA reaching the nucleus for gene expression (see mechanistic foundation).

Evidence & Benchmarks

• PEI, MW 40,000 achieves 60–80% transfection efficiency in HEK-293 cells under serum-containing conditions (see Table 2, Roach 2024).
• DNA/PEI complexes remain stable in 10% fetal bovine serum (FBS) for at least 4 hours at 37°C (Figure 3, Roach 2024).
• Transfection efficiency and cell viability are optimal at a DNA:PEI mass ratio of 1:3 (w/w) in standard DMEM, pH 7.4, with 5% CO₂ (see internal update).
• PEI-based transfection is compatible with scales from 0.1 mL (96-well) to 100 L (bioreactor), with protocol adjustments for mixing and complexation time (manufacturer’s protocol, APExBIO).
• PEI-stabilized nanoparticles demonstrated efficient delivery of both DNA and mRNA payloads in vitro, with preserved mesoscale size distribution critical for targeted delivery (Roach 2024, Results).

Applications, Limits & Misconceptions

Polyethylenimine Linear (PEI), MW 40,000 is validated for a variety of applications:

• DNA transfection in HEK-293, CHO-K1, HepG2, and HeLa cells for recombinant protein production and transient gene expression.
• Facilitating mRNA and siRNA delivery in nanoparticle formulation research (Roach 2024).
• Workflow scalability from microplate to industrial bioreactor systems.
• Endocytosis-mediated DNA uptake in the presence of serum.

For a broader perspective on advanced gene delivery and comparison to other cationic polymers, see this mechanistic foundation article, which details how PEI MW 40,000’s proton-sponge effect distinguishes it from other carriers.

Common Pitfalls or Misconceptions

• PEI MW 40,000 is not suitable for in vivo administration due to toxicity and lack of regulatory approval for therapeutic use.
• Nonlinear (branched) PEI is not equivalent—linear PEI exhibits superior transfection efficiency and lower cytotoxicity in most cell lines (see update).
• Transfection efficiency is highly dependent on cell density and DNA:PEI ratio; suboptimal conditions can lead to reduced gene expression or increased cytotoxicity.
• PEI complexes are not compatible with all primary cell types, especially those with high sensitivity to cationic polymers.
• Repeated freeze–thaw cycles degrade performance; aliquot and store at -20°C for long-term stability (manufacturer’s protocol).

Workflow Integration & Parameters

The K1029 kit (Polyethylenimine Linear (PEI), MW 40,000) from APExBIO is supplied as a 2.5 mg/mL aqueous solution in 4 mL or 8 mL vials. For best performance:

• Store at -20°C for long-term use; keep working aliquots at 4°C to minimize freeze–thaw cycles.
• Prepare DNA/PEI complexes in a neutral buffer (e.g., HEPES or PBS, pH 7.0–7.4) and incubate for 15–20 minutes at room temperature before cell application.
• Use a DNA:PEI (w/w) ratio of 1:3 for most mammalian cell transfections; optimize for each cell line and experimental scale.
• Compatible with serum-containing media, allowing streamlined workflows without medium exchange.
• Scale up by maintaining constant DNA:PEI ratio and adjusting total reagent volume accordingly.

This article extends the discussion from this internal benchmark, providing detailed evidence and mechanistic rationale for protocol optimization and large-scale implementation not previously covered.

Conclusion & Outlook

Polyethylenimine Linear (PEI), MW 40,000 is a highly effective and scalable DNA transfection reagent for in vitro studies, enabling robust and reproducible gene expression in mammalian cell lines. Its serum compatibility, broad applicability, and validated performance make it a benchmark tool for molecular biology, functional genomics, and bioproduction. Ongoing research continues to refine its use in advanced nucleic acid delivery systems and nanoparticle formulations (Roach 2024). For comprehensive mechanistic insights and protocol comparisons, see this article, which this review updates with recent quantitative benchmarks and expanded workflow guidance.